Genetronics Acquires Inovio
Genetronics Biomedical, a late-stage developer of oncology and other therapies using electroporation to deliver drugs and nucleic acids, has acquired Oslo-based Inovio.
Inovio's use of electroporation for gene therapy and DNA vaccines is a complement to Genetronics' existing electroporation therapy program. The acquisition expands Genetronics' intellectual property in electroporation, expands the number of agreements with major pharmaceutical companies, and provides for the near-term initiation of a Phase I/II DNA vaccine clinical trial.
Genetronics is moving its lead product, the MedPulser Electroporation Therapy System, through premarketing studies for head and neck cancer and skin cancer in Europe, where it has CE Mark accreditation, and a Phase III pivotal study for recurrent head and neck cancer in the U.S.